【24h】

Current guidelines for the treatment and prevention of nosocomial infections.

机译:当前治疗和预防医院感染的指南。

获取原文
获取原文并翻译 | 示例
           

摘要

Nosocomial infections (NIs) are among the most difficult problems confronting clinicians who deal with severely ill patients. The incidence of these hospital-acquired infections varies with the size of hospitals, with specialities of wards, and with many other factors such as length of hospital stay, local trends in antibiotic usage, nursing and hygiene conditions, hospital design and geographical distribution of patients at risk. An average incidence of NI can be estimated at 5 to 10%, with higher rates in large university hospitals, reaching up to 28% in the intensive care unit (ICU). Changing epidemiology of NI and emerging resistance problems have resulted in evolving strategies of antibiotic usage in patients at risk. Several recent antibiotic resistance problems have been identified, for instance in Gram-positive organisms, and have been surveyed, in addition to those previously well known in Gram-negative bacilli. The choice of empiric antibiotic therapy for the treatment of any NI before microbiology is available has become a difficult challenge, requiring: (i) surveillance data on a regular basis of predominant organisms in units at risk; (ii) surveillance of the current resistance patterns of these organisms; (iii) identification of outbreaks involving the prevalent organisms, using modern molecular techniques for typing the strain and assess cross-contamination. In documented infection, monotherapy vs combination therapy has been often discussed in the treatment of serious Gram-negative hospital infections, but these concepts vary with the site of infection, the nature of organism involved and its pattern of resistance, the kind of antibiotic which may more or less quickly select resistant mutants. Antibiotic therapy concepts vary significantly between countries, and combinations either empirical or based on laboratory data are often preferred in European countries than in the US. Frequent collaborative studies and an increasing communication between experts of different countries, make guidelines and consensus conferences, established in a particular country, useful elsewhere and may contribute to improvement in the management of NI. Guidelines for the prevention and the control of NI are well established in many developed countries and they may have resulted in the improvement of the prevention and the treatment of NI. However, there is still potential progress that should be made, including individual preventive practices, improvement in nursing practices, control of antibiotic use, trend to shorten the hospital stay and early discharge from hospital, which results in significant cost savings.
机译:医院感染(NIs)是处理重症患者的临床医生面临的最困难的问题之一。这些医院获得性感染的发生率随医院规模,病房专长以及许多其他因素而变化,例如住院时间长短,抗生素使用的局部趋势,护理和卫生状况,医院设计和患者的地理分布有风险。 NI的平均发病率估计为5%至10%,在大型大学医院中更高,在重症监护病房(ICU)中高达28%。 NI流行病学的变化和新出现的耐药性问题导致了处于风险中的患者不断发展的抗生素使用策略。除了以前在革兰氏阴性杆菌中众所周知的那些问题之外,还发现了一些最近的抗生素耐药性问题,例如在革兰氏阳性生物中,并进行了调查。在获得微生物学之前,选择经验性抗生素疗法来治疗任何NI已成为一项艰巨的挑战,这要求:(i)定期对处于危险中的单位中的主要生物进行监测数据; (ii)监测这些生物体目前的抗药性模式; (iii)使用现代分子技术来确定涉及流行生物的暴发,以对菌株进行分型并评估交叉污染。在有记录的感染中,在严重革兰氏阴性医院感染的治疗中经常讨论单一疗法还是联合疗法,但是这些概念随感染部位,所涉及生物体的性质及其耐药模式,可能使用的抗生素种类而异。或多或少迅速地选择了抗性突变体。各国之间的抗生素治疗概念差异很大,在欧洲国家中,经验性或基于实验室数据的组合通常比美国更受欢迎。频繁的合作研究以及不同国家的专家之间日益增加的交流,使得在特定国家/地区建立的指南和共识会议在其他地方也很有用,并且可能有助于改善NI的管理。在许多发达国家,NI的预防和控制指南已经确立,可能导致NI的预防和治疗得到改善。但是,仍然需要进行潜在的进步,包括个人的预防措施,护理措施的改善,抗生素的使用控制,缩短住院时间和及早出院的趋势,从而可以节省大量成本。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号